Merck's Emend To Be Covered Under Part B In Draft CMS Coverage Decision
This article was originally published in The Pink Sheet Daily
Executive Summary
The anti-emetic would be covered by Medicare Part B when used in combination with a 5-HT3 antagonist and dexamethasone in patients refractory to standard treatments, CMS says. Other uses of Emend would be covered under Part D beginning in 2006.